NuvOx Welcomes Wilson W. Cheung as An Independent Board Member

Tucson, AZ – September 26, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that it has appointed Mr. Wilson W. Cheung, CPA, as an independent Board Member.

Evan Unger, M.D., Co-founder and Executive Chairman of NuvOx, said, “We are extremely fortunate to have Wilson to join us as a board member. Wilson is a seasoned Wall Street veteran with over 30 years of experience in finance, compliance, investor relations, cross border transactions, fund-raising and corporate leadership at both public and private companies. He has been a public company CFO since 2003, and for the past 12 years working for pharma and biotech companies. Wilson brings the deep experiences to advise us to the next stage of success.” 

Wilson Cheung said, “It is my great privilege to join NuvOx’s board. NuvOx’s unique and novel technology has broad application and address grave unmet medical needs. With promising, large impact, I am also deeply impressed by the passion, resilience, and discipline from the team. NuvOx has been able to make stunning progress with outstanding capital efficiency and under challenging market condition. I am excited to work with the rest of the board members and the management team.”

“We are thrilled to have Wilson as an independent board member,” added Rong Wang, President and CEO of NuvOx, “Wilson’s wealth of knowledge and leadership, especially in the biopharma industry, will play a critical role in advising and guiding us through the stage of high growth. We look forward to working with him in our rapid advance of our technology.”

Wilson Cheung graduated from the University of California, Los Angeles with a B.A. in Economics/Business. He is a California certified public accountant and a certified director of corporate governance from UCLA’s Anderson Graduate School of Management.

About NuvOx:

NuvOx is a privately held clinical-stage biopharmaceutical company developing a novel platform of oxygen therapeutics for the treatment of diseases where hypoxia plays a role. Hypoxia, or low oxygen, is responsible for resistance to cancer treatment, brain damage in stroke, and the death of patients with acute respiratory distress syndrome (ARDS).

The Company’s drug candidate- NanO₂ represents a potentially disruptive platform technology addressing multiple unmet needs, with positive results demonstrated in two completed Phase Ib/II studies: one in glioblastoma as a radiosensitizer and the other in stroke as a neuroprotectant. It was shown to be the most promising oxygen therapeutic among 74 clinical-stage compounds in a literature review. It has safety and efficacy data in 7+ indications in various preclinical and clinical stages, including Orphan Drug Designation for both glioblastoma and sickle cell anemia.

The product can refer to safety data in ~2,000 subjects. The product is designed to be synergistic, rather than competitive with standard of care. The company also has a strong IP portfolio: 11 patent families, 11 issued US patents and 31 foreign equivalents.

NuvOx is conducting a Phase IIb clinical trial as a radiosensitizer in treatment of glioblastoma, has started a Phase IIb clinical trial for NanO₂ in the treatment of acute ischemic stroke, funded by the UK government, and is conducting a Phase Ib clinical trial for NanO₂ in the treatment of respiratory distress.

Investor Relations

Hanover International, Inc.

E: ka@hanoverintlinc.com

Forward-looking statement

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws.  Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "antici-pates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.  The forward-looking statements include statements regarding our first-in-class product being able to help ARDS patients; the potential of NanO₂ to restore blood oxygen levels, decrease lung inflammation, and improve survival; the EXTEND Trial paving the way for NanO₂ as treatment for ARDS; and NanO₂ representing a potentially disruptive platform technology addressing multiple unmet needs, NanO₂ being synergistic with standard of care and plans to start a Phase IIb clinical trial for NanO₂ in treatment of acute ischemic stroke and a Phase Ib clinical trial for NanO₂ in treatment of respiratory distress. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees. These risks should not be construed as exhaustive. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.